VolitionRx Limited (VNRX) Research

VolitionRx Limited is an international epigenetics firm that specializes in pioneering advanced blood tests. These diagnostics are developed to aid in the global detection of various cancers and other diseases. Their innovative product suite includes Nu.Q, engineered for cancer detection; Nu.Q Nets, which monitors immune system health; Nu.Q Vet, a cancer screening solution tailored for animal applications; Nu.Q Capture, designed to enhance diagnostic precision by concentrating samples; and Nu.Q Discover, a specialized platform for nucleosome profiling. The cornerstone of their blood test technology is their proprietary Nucleosomics platform. The company maintains its headquarters in Austin, Texas.

Market snapshot

Symbol
VNRX
Price
$1.43
Day change
+4.38%
Market cap
$8.4M
P/E ratio
-0.40x
52-week range
1.3-18.8
Sector
Healthcare
Industry
Medical - Diagnostics & Research
Next earnings
in 2 months

Peer companies

  • Aligos Therapeutics, Inc. (ALGS)
  • Biodesix, Inc. (BDSX)
  • Cytosorbents Corporation (CTSO)
  • INmune Bio, Inc. (INMB)
  • Medicus Pharma Ltd. Common Stock (MDCX)
  • Mersana Therapeutics, Inc. (MRSN)
  • Inotiv, Inc. (NOTV)
  • Skye Bioscience, Inc. (SKYE)

Recent insider activity

  • Forterre Gael — F-InKind (5251 shares) on 2026-03-17
  • Rootsaert Rodney Gerard — F-InKind (3948 shares) on 2026-03-17
  • Micallef Jacob Vincent — F-InKind (5310 shares) on 2026-03-17
  • Plummer Nicholas — F-InKind (7003 shares) on 2026-03-17
  • Rootsaert Rodney Gerard — F-InKind (3321 shares) on 2026-03-01

Open VolitionRx Limited (VNRX) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.